ストックスクリーナーアプリを入手
59.44
1.95%
-1.18
アフターアワーズ：
59.00
-0.44
-0.74%
前日終値:
$60.62
開ける：
$60.89
24時間の取引高:
1.21M
Relative Volume:
0.75
時価総額：
$5.60B
収益：
$536.20M
当期純損益:
$-45.64M
株価収益率:
-111.14
EPS:
-0.5348
ネットキャッシュフロー:
$-28.94M
1週間 パフォーマンス:
-5.29%
1か月 パフォーマンス:
-11.30%
6か月 パフォーマンス:
+115.67%
1年 パフォーマンス:
+141.58%
1日の値動き範囲:
$59.05
$60.89
1週間の範囲:
$58.32
$63.64
52週間の値動き範囲:
$22.05
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
59.44 | 5.60B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
RTRX5376243 Bond Profile: Coupon and Redemption - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $89.00 - GuruFocus
Guggenheim raises Travere Therapeutics stock price target on patent By Investing.com - Investing.com Canada
Understanding the Setup: (TVTX) and Scalable Risk - news.stocktradersdaily.com
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - marketscreener.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - BioSpace
Travere receives patent allowance for FILSPARI use in FSGS - Investing.com
Travere TherapeuticsReceives USPTO Notice Of Allowance For Filspari Patent In FSGS - TradingView
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026 - Yahoo Finance
Why Everyone Is Watching Travere Therapeutics (TVTX) Today - simplywall.st
Travere Therapeutics appoints new CEO Bradley Campbell - The Globe and Mail
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today - finance.yahoo.com
TVTX Reiterated by Wedbush -- Price Target Maintained at $76.00 - GuruFocus
Travere Therapeutics Names Bradley Campbell CEO - Contract Pharma
Wedbush reiterates Outperform rating on Travere Therapeutics, $76 price target - TradingView
HC Wainwright & Co. reiterates Buy rating on Travere Therapeutics, $67 price target - TradingView
TVTX Looks 64.1% Overvalued on GF Value™ - GuruFocus
Travere Therapeutics Announces Planned Chief Executive Officer Transition - BioSpace
Travere Therapeutics stock falls amid CEO transition news By Investing.com - Investing.com Nigeria
Travere Therapeutics Names Bradley Campbell CEO Effective December 1, 2026 - Minichart
Travere Therapeutics stock falls amid CEO transition news - Investing.com
Travere Therapeutics CEO Eric Dube to step down in December By Investing.com - Investing.com Nigeria
Travere Therapeutics President and CEO Eric Dube Plans to Step Down - marketscreener.com
Travere Therapeutics CEO Eric Dube to step down in December - Investing.com India
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026 - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum - ChartMill
Travere Therapeutics CFO Cline Christopher R. Executes Options and Sells Shares on September 15, 2026 - Kalkine Media
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing - marketscreener.com
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Canada
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com Australia
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Australia
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Australia
Travere therapeutics CEO Eric Dube sells $25.4m in shares - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere therapeutics CEO Eric Dube sells $25.4m in shares By Investing.com - Investing.com Canada
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) EVP Sells $10,955,439.31 in Stock - MarketBeat
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum - Yahoo Finance
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):